Fig. 5: A1874 oral administration inhibits colon cancer xenograft growth in SCID mice.
From: The therapeutic effect of the BRD4-degrading PROTAC A1874 in human colon cancer cells
The SCID mice bearing pCan1 colon cancer xenografts were treated with A1874 (20 mg/kg body weight, oral administration, daily for 21 days) or the vehicle control (“Veh”); Tumor volumes (a) and mice body weights (d) were recorded weekly. The estimated daily tumor growth was calculated by using the described formula (b). At Day-42/D42, tumors of the two groups were isolated and weighted (c). At treatment Day7 (D7), one tumor of each group was isolated, and tumors were homogenized. Expression of the listed proteins in tumor tissue lysates was tested (e, f). The GSH/GSSG ratio in tumor tissue lysates was examined (g). Expression of listed proteins was quantified and normalized to the loading control (e, f). Data were presented as mean ± standard deviation (SD). *P < 0.05 vs. “Veh” group.
